Oncology and Non-Small Cell Lung Cancer
Bergenbio ASA’s clinical research is centred on advanced and metastatic non-squamous non-small cell lung cancer, with particular attention to patients lacking actionable mutations. The sponsor’s work in this area includes disease settings where treatment options are limited and where tumour biology may influence response to therapy.
- Non-squamous NSCLC
- Advanced-stage lung cancer
- Metastatic solid tumours
Research activity also includes lung cancer with STK11 mutation, reflecting interest in molecularly defined patient groups within thoracic oncology.
Chemo-Immunotherapy Combinations
The sponsor’s trial portfolio focuses on combining bemcentinib with chemo-immunotherapy in the first-line treatment setting for advanced lung cancer. This therapeutic area brings together cytotoxic chemotherapy and immuno-oncology approaches in patients with newly diagnosed disease.
- First-line treatment
- Chemo-immunotherapy
- Combination therapy
Interest extends to treatment strategies for patients without actionable genomic alterations, where combined modalities are being evaluated in a solid tumour setting.
Targeted Therapy in Molecularly Defined Disease
Bergenbio ASA is active in research addressing STK11-mutated lung cancer, a biomarker-defined subgroup within non-small cell lung cancer. This places emphasis on molecular stratification and the therapeutic relevance of specific tumour alterations.
- STK11 mutation
- Biomarker-defined cancer
- Molecular oncology
The sponsor’s clinical interest is concentrated on identifying treatment activity in genetically characterised disease populations.
